A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2-p53 antagonist BI 907828 in patients (pts) with solid tumours

被引：2

作者：

Schoeffski, P. ^{[1
]}

Yamamoto, N. ^{[2
]}

Bauer, T. ^{[3
]}

Patel, M. ^{[4
]}

Gounder, M. M. ^{[5
]}

Geng, J. ^{[6
]}

Sailer, R. ^{[7
]}

Jayadeva, G. ^{[8
]}

Lorusso, P. ^{[9
]}

机构：

[1] Univ Hosp Leuven, Leuven Canc Inst, Dept Gen Med Oncol, Leuven, Belgium

[2] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan

[3] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[4] Florida Canc Specialists Res Inst, Sarah Cannon Res Inst, Sarasota, FL USA

[5] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[6] Boehringer Ingelheim Pharmaceut Inc, Biostatist & Data Sci, Ridgefield, CT USA

[7] Boehringer Ingelheim Int GmbH, Dept Translat Med & Clin Pharmacol, Ingelheim, Germany

[8] Boehringer Ingelheim Int GmbH, Dept Med, Therapy Area Oncol, Ingelheim, Germany

[9] Yale Univ, Yale Canc Ctr, Sch Med, New Haven, CT USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.581

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

452O

引用

页码：S743 / S743

页数：1

共 50 条

[1] A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2ep53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours
Schoeffski, P.
Lorusso, P.
Yamamoto, N.
Lugowska, I.
Garcia, V. Moreno
Lauer, U.
Hu, C.
Jayadeva, G.
Lahmar, M.
Gounder, M.
ANNALS OF ONCOLOGY, 2023, 34 : S472 - S473
[2] A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.
LoRusso, Patricia
Gounder, Mrinal M.
Patel, Manish R.
Yamamoto, Noboru
Bauer, Todd Michael
Laurie, Scott
Grempler, Rolf
Davenport, Teffany
Geng, Junxian
Rohrbacher, Maren
Lahmar, Mehdi
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS)
LoRusso, Patricia
Gounder, Mrinal M.
Yamamoto, Noboru
Patel, Manish R.
Bauer, Todd Michael
Geng, Junxian
Sailer, Reinhard
Tang, Yuefen
Jayadeva, Girish
Schoffski, Patrick
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma
Gounder, M.
Patel, M. R.
Yamamoto, N.
Bauer, T. M.
Laurie, S.
Perez-Pitarch, A.
Geng, J.
Cheng, J.
Lahmar, M.
Lorusso, P.
ANNALS OF ONCOLOGY, 2021, 32 : S1124 - S1125
[5] A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS)
Gounder, Mrinal M.
Yamamoto, Noboru
Patel, Manish R.
Bauer, Todd Michael
Schoffski, Patrick
Grempler, Rolf
Durland-Busbice, Sara
Geng, Junxian
Maerten, Angela
LoRusso, Patricia
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] Efficacy and safety of brigimadlin (BI 907828), an MDM2-p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials
Macarulla, Teresa
Yamamoto, Noboru
Tolcher, Anthony W.
Hafez, Navid
Lugowska, Iwona
Ramlau, Rodryg
Geng, Junxian
Li, Jian
Teufel, Michael
Maerten, Angela
Lorusso, Patricia
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 487 - 487
[7] Efficacy and safety of the MDM2-p53 antagonist BI 907828 in patients with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials.
Yamamoto, Noboru
Tolcher, Anthony W.
Hafez, Navid
Lugowska, Iwona
Ramlau, Rodryg
Gounder, Mrinal M.
Geng, Junxian
Li, Jian
Teufel, Michael
Maerten, Angela
LoRusso, Patricia
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 543 - 543
[8] The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
LoRusso, Patricia
Yamamoto, Noboru
Patel, Manish R.
Laurie, Scott A.
Bauer, Todd M.
Geng, Junxian
Davenport, Teffany
Teufel, Michael
Li, Jian
Lahmar, Mehdi
Gounder, Mrinal M.
CANCER DISCOVERY, 2023, 13 (08) : 1802 - 1813
[9] A phase Ia/Ib, open label, multicenter, dose -escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors.
Chong, Curtis Robert
Bauer, Todd Michael
Laurie, Scott Andrew
Patel, Manish R.
Yamamoto, Noboru
Davenport, Teffany
Geng, Junxian
Gibson, Neil
Vallaster, Markus P.
LoRusso, Patricia
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10] Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2-p53 antagonist
Peltzer, Alexander
Hesse, Raphael
Gounder, Mrinal M.
Yamamoto, Noboru
Patel, Manish R.
Laurie, Scott
Bauer, Todd Michael
Teufel, Michael
Geng, Junxian
LoRusso, Patricia
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →